journal article·2022-04

The emerging role of bile acids as critical components in nanotechnology and bioengineering: Pharmacology, formulation optimizers and hydrogel-biomaterial applications

Bozica Kovacevic, Melissa Jones, Corina Ionescu, Daniel Walker, Susbin Wagle, Jacqueline Chester, Thomas Foster, Daniel Brown, Momir Mikov, Armin Mooranian, Hani Al-Salami

Biomaterials· Volume 283
Publisher page

Abstract

The role of endogenous bile acids as lipid stabilizers aiding uptake of lipophilic nutrients via micelle formation and saponification effects is well documented and precedes their growing applications in pharmaceutical sciences. Their utility stems from their unique physico-chemical profile and ability to modulate immune cell signalling pathways. It has been shown that bile acids alter specific receptor-mediated pathways of cellular respiration and metabolism, providing potential clinical therapies for cardio-metabolic disorders such as diabetes mellitus, hypercholesterolemia, and heart disease. Additionally, some bile acids exert profound anti-oxidant, anti-inflammatory and immunosuppressant properties, and are effective at reducing blood pressure and alleviating hypertension. Their unique amphoteric properties and proven ability as permeability enhancers make them a desirable pharmaceutical excipient. When incorporated with various carbohydrates, polymers, hydrogels and/or polyelectrolytes to form micro- or nano-capsules, they provide enhanced thermodynamic, osmotic and structural stability, and cater for controlled delivery via specific tissue targeting, pH dependant release and temperature guided sol-gel complexation. Additionally, due to their immunosuppressant properties, they enhance the immunogenicity of encapsulated cells, increasing the feasibility of bioartificial organs as transplantable therapeutics. This review explores existing and future applications of bile acids and provides a synopsis of their role in advanced, novel therapeutic delivery systems.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Drug Transport and Resistance Mechanisms · Nanoparticle-Based Drug Delivery · Advanced Drug Delivery Systems

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. Characterization of a novel bile acid-based delivery platform for microencapsulated pancreatic beta-cells10.3109/21691401.2014.934457 ↗
2. Advances in biocompatibility and physico-chemical characterization of microspheres for cell encapsulation10.1016/j.addr.2013.07.010 ↗
3. The current state of pancreas transplantation10.1038/nrendo.2013.138 ↗
4. International trial of the edmonton protocol for islet transplantation10.1056/NEJMoa061267 ↗
5. A silk-based encapsulation platform for pancreatic islet transplantation improves islet function in vivo10.1002/term.1990 ↗
6. Clinical pancreatic islet transplantation10.1038/nrendo.2016.178 ↗
7. The synergy of scaffold-based and scaffold-free tissue engineering strategies10.1016/j.tibtech.2018.01.005 ↗
8. A decade of progress in tissue engineering10.1038/nprot.2016.123 ↗
9. Cell delivery mechanisms for tissue repair10.1016/j.stem.2008.02.005 ↗
10. 3D bioprinting of collagen to rebuild components of the human heart10.1126/science.aav9051 ↗
11. Endocrine functions of bile acids10.1038/sj.emboj.7601049 ↗
12. Bile acid metabolism and the pathogenesis of type 2 diabetes10.1007/s11892-011-0187-x ↗
13. Potentials and limitations of bile acids in type 2 diabetes mellitus: applications of microencapsulation as a novel oral delivery system
14. Mooranian A, Negrulj R, Chen-Tan N, Fakhoury M, Jones F, Arfuso F, et al., editors. NOVEL MULTICOMPARTMENTAL BILE ACID-BASED MICROCAPSULES FOR PANCREATIC beta-CELL TRANSPLANTATION. IPITA-IXA-CTS 2015 Joint Congress of the International-Pancreas-And-Islet-Transplantation-Association, International-Xenotransplantation-Association and Cell-Transplant-Society; 2015/11/01/; Melbourne, AUSTRALIA United States: LIPPINCOTT WILLIAMS & WILKINS.
15. Mooranian A, Negrulj R, Chen-Tan N, Fakhoury M, Jones F, Arfuso F, et al., editors. Novel multicompartmental bile acid-based microcapsules for pancreatic beta-cell transplantation. IPITA/IXA/CTS Joint Congress; 2015/11/01/; Melbourne, AUSTRALIA United States: WILEY-BLACKWELL.
16. Developments in bile salt based therapies: a critical overview10.1016/j.bcp.2018.12.018 ↗
17. Interaction of lactic acid bacteria with the gut immune system10.1038/sj.ejcn.1601658 ↗
18. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells10.1016/j.immuni.2010.06.001 ↗
19. Effect of diabetes during pregnancy on maternal and neonatal bile acid metabolism in the rat10.3181/00379727-165-41010 ↗
20. Unidirectional flux rate of cholesterol and fatty acids into the intestine of rats with drug-induced diabetes mellitus: effect of variations in the effective resistance of the unstirred water layer and the bile acid micelle10.1016/S0022-2275(20)34797-0 ↗
21. The bile acid membrane receptor TGR5: a valuable metabolic target10.1159/000324126 ↗
22. Cyp2c70 is responsible for the species difference in bile acid metabolism between mice and humans10.1194/jlr.M071183 ↗
23. New therapeutic concepts in bile acid transport and signaling for management of cholestasis10.1002/hep.28991 ↗
24. Heart and bile acids – clinical consequences of altered bile acid metabolism10.1016/j.bbadis.2017.12.039 ↗
25. [Dissolution of cholesterol gallstones by long-term administration of ursodeoxycholic acid]
26. Negrulj R, Mooranian A, Al-Salami H. Potentials and Limitations of Bile Acids in Type 2 Diabetes Mellitus: Applications of Microencapsulation as a Novel Oral Delivery System2013. 49-59 p.
27. Bile acid transporters10.1194/jlr.R900012-JLR200 ↗
28. Diurnal variations of mouse plasma and hepatic bile acid concentrations as well as expression of biosynthetic enzymes and transporters10.1371/journal.pone.0016683 ↗
29. The enterohepatic circulation of bile salts10.1001/archinte.1972.03650040078008 ↗
30. Nuclear bile acid receptor farnesoid X receptor meets nuclear factor-κB: new insights into hepatic inflammation10.1002/hep.22668 ↗
31. Bile salt biotransformations by human intestinal bacteria10.1194/jlr.R500013-JLR200 ↗
32. Bile acid transporters and regulatory nuclear receptors in the liver and beyond10.1016/j.jhep.2012.08.002 ↗
33. Compromised intestinal lipid absorption in mice with a liver-specific deficiency of liver receptor homolog 110.1128/MCB.00852-07 ↗
34. Liver receptor homolog-1 regulates bile acid homeostasis but is not essential for feedback regulation of bile acid synthesis10.1210/me.2007-0565 ↗
35. Update on FXR biology: promising therapeutic target?10.3390/ijms19072069 ↗
36. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis10.1126/science.1198363 ↗
37. New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond10.1016/j.jhep.2015.02.023 ↗
38. REV-ERBalpha participates in circadian SREBP signaling and bile acid homeostasis10.1371/journal.pbio.1000181 ↗
39. Application of bile acids in drug formulation and delivery10.1080/21553769.2013.879925 ↗
40. Bile acid signaling in lipid metabolism: metabolomic and lipidomic analysis of lipid and bile acid markers linked to anti-obesity and anti-diabetes in mice10.1016/j.bbalip.2014.04.008 ↗
41. Primary bile acid chenodeoxycholic acid-based microcapsules to examine β-cell survival and the inflammatory response10.1007/s12668-016-0198-9 ↗
42. The impact of allylamine-bile acid combinations on cell delivery microcapsules in diabetes10.1080/02652048.2016.1228703 ↗
43. Novel chenodeoxycholic acid-sodium alginate matrix in the microencapsulation of the potential antidiabetic drug, probucol. An in vitro study10.3109/02652048.2015.1065922 ↗
44. Micelle formation of sodium cholate and solubilization into the micelle10.1016/S0005-2760(98)00090-3 ↗
45. Bile salts and derivatives: rigid unconventional amphiphiles as dispersants, carriers and superstructure building blocks10.1016/j.cocis.2015.08.004 ↗
46. Bile acid physiology10.5604/01.3001.0010.5493 ↗
47. Bile acids improve the antimicrobial effect of rifaximin10.1128/AAC.00161-10 ↗
48. Head group-independent interaction of phospholipids with bile salts. A fluorescence and EPR study10.1016/S0022-2275(20)34478-3 ↗
49. Self-assembly in aqueous bile salt solutions10.1016/j.cocis.2009.11.010 ↗
50. Bile salts: natural surfactants and precursors of a broad family of complex amphiphiles10.1021/acs.langmuir.8b02657 ↗
51. Self-assembly of a bile acid dimer in aqueous solutions: from nanofibers to nematic hydrogels10.1021/acs.langmuir.6b04033 ↗
52. The bile acid membrane receptor TGR5: a novel pharmacological target in metabolic, inflammatory and neoplastic disorders10.3109/10799893.2013.802805 ↗
53. Innovative microcapsules for pancreatic β-cells harvested from mature double-transgenic mice: cell imaging, viability, induced glucose-stimulated insulin measurements and proinflammatory cytokines analysis10.1007/s11095-017-2138-y ↗
54. A prevascularized subcutaneous device-less site for islet and cellular transplantation10.1038/nbt.3211 ↗
55. Bioengineering the endocrine pancreas: intraomental islet transplantation within a biologic resorbable scaffold10.2337/db15-1525 ↗
56. Re-engineering islet cell transplantation10.1016/j.phrs.2015.02.010 ↗
57. Evolution of islet transplantation for the last 30 years10.1097/MPA.0000000000000391 ↗
58. Islets transplanted in immunoisolation devices: a review of the progress and the challenges that remain10.1210/er.2010-0026 ↗
59. In situ three-dimensional printing for reparative and regenerative therapy10.1007/s10544-019-0372-2 ↗
60. Direct writing alginate bioink inside pre-polymers of hydrogels to create patterned vascular networks10.1007/s10853-019-03447-2 ↗
61. The pathology of the foreign body reaction against biomaterials10.1002/jbm.a.35958 ↗
62. Zwitterionic hydrogels implanted in mice resist the foreign-body reaction10.1038/nbt.2580 ↗
63. The provisional matrix: setting the stage for tissue repair outcomes10.1016/j.matbio.2017.04.003 ↗
64. The foreign body response demystified10.1021/acsbiomaterials.8b00252 ↗
65. A guiding map for inflammation10.1038/ni.3790 ↗
66. Limiting inflammation - the negative regulation of NF-B and the NLRP3 inflammasome10.1038/ni.3772 ↗
67. Toll-like receptor control of the adaptive immune responses10.1038/ni1112 ↗
68. Pathogen recognition and innate immunity10.1016/j.cell.2006.02.015 ↗
69. Human neutrophils in the saga of cellular heterogeneity: insights and open questions10.1111/imr.12448 ↗
70. IL-17 and IL-22 in immunity: driving protection and pathology10.1002/eji.201646723 ↗
71. Historical insights into cytokines10.1002/eji.200737772 ↗
72. Acute phase proteins as promising biomarkers: perspectives and limitations for human and veterinary medicine10.1002/prca.201600028 ↗
73. The role of complement in inflammatory diseases from behind the scenes into the spotlight10.2353/ajpath.2007.070166 ↗
74. Human sickness behavior: ultimate and proximate explanations10.1002/ajpa.22698 ↗
75. The harmful role of c5a on innate immunity in sepsis10.1159/000317194 ↗
76. Tissue macrophages: heterogeneity and functions10.1186/s12915-017-0392-4 ↗
77. Macrophages: versatile players in renal inflammation and fibrosis10.1038/s41581-019-0110-2 ↗
78. Macrophages reprogrammed in vitro towards the M1 phenotype and activated with LPS extend lifespan of mice with ehrlich ascites carcinoma10.12659/MSMBR.895563 ↗
79. Antifouling poly(β-peptoid)s10.1021/bm200368p ↗
80. Biocompatibility of implants: lymphocyte/macrophage interactions10.1007/s00281-011-0244-1 ↗
81. Inflammation and wound healing: the role of the macrophage10.1017/S1462399411001943 ↗
82. Biomedical implant capsule formation: lessons learned and the road ahead10.1097/SAP.0000000000000287 ↗
83. Regulation and functions of the IL-10 family of cytokines in inflammation and disease10.1146/annurev-immunol-031210-101312 ↗
84. IL-1: discoveries, controversies and future directions10.1002/eji.201040319 ↗
85. The role of M2 macrophages in the progression of chronic kidney disease following acute kidney injury10.1371/journal.pone.0143961 ↗
86. The role of macrophage phenotype in vascularization of tissue engineering scaffolds10.1016/j.biomaterials.2014.02.012 ↗
87. Reflex principles of immunological homeostasis10.1146/annurev-immunol-020711-075015 ↗
88. Alginate-deoxycholic acid interaction and its impact on pancreatic Β-cells and insulin secretion and potential treatment of type 1 diabetes10.1007/s12247-016-9248-7 ↗
89. Bile acid-polymer-probucol microparticles: protective effect on pancreatic beta-cells and decrease in type 1 diabetes development in a murine model10.1080/10837450.2019.1665069 ↗
90. Mesenchymal stromal cell therapeutic delivery: translational challenges to clinical application10.3389/fimmu.2019.01645 ↗
91. Therapeutic mesenchymal stromal cells for immunotherapy and for gene and drug delivery10.1016/j.omtm.2020.01.005 ↗
92. Characterization of a novel bile acid-based delivery platform for microencapsulated pancreatic beta-cells10.3109/21691401.2014.934457 ↗
93. Designing anti-diabetic β-cells microcapsules using polystyrenic sulfonate, polyallylamine, and a tertiary bile acid: morphology, bioenergetics, and cytokine analysis10.1002/btpr.2223 ↗
94. The incorporation of water-soluble gel matrix into bile acid-based microcapsules for the delivery of viable β-cells of the pancreas, in diabetes treatment: biocompatibility and functionality studies10.1007/s13346-015-0268-5 ↗
95. Viability and topographical analysis of microencapsulated β-cells exposed to a biotransformed tertiary bile acid: an ex vivo study10.1504/IJNBM.2016.079684 ↗
96. Chasing the paradigm: clinical translation of 25 Years of tissue engineering10.1089/ten.tea.2019.0032 ↗
97. Decellularized human liver as a natural 3D-scaffold for liver bioengineering and transplantation10.1038/srep13079 ↗
98. Development of a coaxial 3D printing platform for biofabrication of implantable islet-containing constructs10.1002/adhm.201801181 ↗
99. Mooranian · Artificial Cells, Nanomedicine, and Biotechnology · 2018 · 46 · 115610.1080/21691401.2017.1362416 ↗
100. Characterization of a novel bile acid-based delivery platform for microencapsulated pancreatic β-cells10.3109/21691401.2014.934457 ↗